Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.
Dr. Charis Teh and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Background: Venetoclax is a highly effective treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that works by inhibiting the BCL2 protein. BCL2
This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients without the high-risk mutation,17p deletion
Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they
Pushing Therapeutic Boundaries in CLLJoint Live Web Broadcast with CLL Society and PeerView Institute Recorded on June 14, 2021 Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the
Making Modern Treatment Choices in CLLOncology Nurse Insights on the Patient Journey and the New Era of Care Recorded on April 22, 2021 CLL Society and PeerView Institute jointly provided a web broadcast in association with the 47th Annual ONS Congress. This NCPD/ILNA-certified program used PeerView’s “Nursing Clinical Consults”
During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.